News stories about Albany Molecular Research (NASDAQ:AMRI) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Albany Molecular Research earned a news impact score of 0.15 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.1271159510747 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Albany Molecular Research (NASDAQ AMRI) opened at 21.76 on Friday. Albany Molecular Research has a 12-month low of $13.01 and a 12-month high of $22.17. The stock’s market capitalization is $906.65 million. The firm has a 50-day moving average of $21.70 and a 200-day moving average of $18.08.

A number of equities research analysts recently commented on AMRI shares. Morgan Stanley cut shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective on the stock. in a research note on Thursday, May 11th. They noted that the move was a valuation call. William Blair restated an “outperform” rating on shares of Albany Molecular Research in a report on Tuesday, May 23rd. J P Morgan Chase & Co lowered shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. First Analysis lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. Finally, BidaskClub lowered shares of Albany Molecular Research from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, The stock currently has an average rating of “Hold” and an average target price of $18.00.

COPYRIGHT VIOLATION WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/13/albany-molecular-research-amri-earns-daily-media-sentiment-score-of-0-15.html.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Insider Buying and Selling by Quarter for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.